Carrassa, Laura Colombo, Ilaria Damia, Giovanna Bertoni, Francesco 2020-08-11 The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be exploited therapeutically. Specifically, we will focus on CHK1, WEE1, ATR, DNA-PK and PARP inhibitors, for which preclinical data as single agents or in combination has been accumulating, fostering their clinical development. The few available clinical data on these inhibitors will also be discussed. application/pdf https://n2t.net/ark:/12658/srd1319258 https://susi.usi.ch/global/documents/319258 https://susi.usi.ch/documents/319258/files/Bertoni_2020_ctr.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ctrv.2020.102090 info:eu-repo/semantics/altIdentifier/ark/12658/srd1319258 info:eu-repo/semantics/openAccess CC BY-NC-ND Cancer treatment reviews. - 2020, vol. 90, p. 11 DNA damage response ATR PARP ATM CHK1 WEE1 Lymphoma DNA-PK info:eu-repo/classification/udc/616 Targeting the DNA damage response for patients with lymphoma : preclinical and clinical evidences http://purl.org/coar/resource_type/c_6501